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Abstract
Purpose We evaluated whether multiplex protein quantification using antibody bar-coding with photocleavable oligonu-
cleotides (NanoString) can be applied to evaluate protein expression in breast cancer FFPE specimens. We also assessed 
whether diagnostic core-cuts fixed immediately at time of procedures and surgical excision sections from routinely fixed 
breast cancers are affected by the same fixation related differences noted using immunohistochemistry (IHC).
Methods The expression of 26 proteins was analysed using NanoString technology in 16 pairs of FFPE breast cancer core-
cuts and surgical excisions. The measurements yielded were compared with those by IHC on Ki67, PgR and HER2 biomark-
ers and pAKT and pERK1/2 phosphorylated proteins.
Results When considered irrespective of sample type, expression measured by the two methods was strongly correlated for 
all markers (p < 0.001; ρ = 0.69–0.88). When core-cuts and excisions were evaluated separately, the correlations between 
NanoString and IHC were weaker but significant except for pAKT in excisions. Surgical excisions showed lower levels of 
8/12 phosphoproteins and higher levels of 4/13 non-phosphorylated proteins in comparison to core-cuts (p < 0.01). Reduced 
p4EBP1, pAMPKa, pRPS6 and pRAF1 immunogenicity in excisions was correlated with tumour size and mastectomy 
specimens showed lower p4EBP1 and pRPS6 expression than lumpectomy (p < 0.05).
Conclusions Our study supports the validity of the new multiplex approach to protein analysis but indicates that, as with IHC, 
caution is necessary for the analysis in excisions particularly of phosphoproteins. The specimen type, tumour size and surgery 
type may lead to biases in the quantitative analysis of many proteins of biologic and clinical interest in excision specimens.
Keywords Breast cancer · Immunohistochemistry · NanoString technology · Multiplex protein analysis · Phosphorylation · 
Tissue fixation
Abbreviations
IHC  Immunohistochemistry
DAB  Diaminobenzidine
IF  Immunofluorescent
FFPE  Formalin-fixed paraffin-embedded
IQR  Interquartile range
RMH  Royal Marsden Hospital
HPF’s  High-power fields
H&E  Haematoxylin and eosin
ERCC  External RNA controls consortium
Introduction
Proteins are currently the most suitable target for anti-
cancer drugs and protein biomarkers may help in ther-
apy stratification. Immunohistochemistry (IHC) for both 
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predictive and prognostic tests based on protein biomark-
ers has been applied to guide oncologists in their use of 
targeted therapies for breast cancer patients [1–3]. How-
ever, standard IHC is still generally considered a semi-
quantitative approach to evaluate protein expression. 
Moreover, accurate IHC analysis is highly dependent on 
the methodology, observer and the quality of the tissue 
[4, 5].
It is well known that visual scoring is inherently subjec-
tive and both intra-observer and inter-observer variability 
have been commonly reported. This variability slows the 
progress of biomarker discovery and delivery of precision 
medicine [6]. Moreover, the most common staining methods 
(such as the “brown staining” with diaminobenzidine, DAB) 
have a limited dynamic range and different batches can pre-
sent variations in the staining intensity in standard IHC. 
Immunofluorescent (IF) staining has improved the quantifi-
cation of proteins [7] and digital pathology can increase the 
reliability and speed of analysis. The degree of agreement 
among manual and the automated methods (‘Man versus 
Machine’ comparison) has been published for the scoring of 
several breast cancer biomarkers, including HER2, ER, PgR 
and Ki67 [6, 8–10]. However, digital image analysis even in 
combination with fluorescence staining is still mainly used 
for the analysis of a single or a few biomarkers per slide and 
both technologies are limited in their availability [11].
Recently, a new method of protein quantification has 
become available with a number of advantages. This uses 
antibody bar-coding with photocleavable DNA oligonuce-
lotides allowing multiplexed quantitative protein measure-
ments and system-wide profiling on small amounts of tissue 
extracts [12]. After oligonucleotide cleavage from antibod-
ies, a hybridization process is done and the oligonucleotide 
tags are quantified using the NanoString  nCounter® Analysis 
System (NanoString Technologies, Seattle, WA, USA) as 
commonly performed for gene expression analysis. Initial 
epitope retrieval and primary antibody binding steps are still 
required as per standard IHC. Therefore, this methodology is 
likely to be affected in a similar way to IHC by pre-analytical 
factors, such as cold ischemic time, intraoperative hypoxia, 
section thickness, type and duration of fixation and proces-
sor protocols [13].
We previously undertook a systematic evaluation of the 
semi-quantitative IHC expression of ER, PgR, HER2, Ki67 
and the phosphorylated proteins pAKT and pERK1/2 in 
core-cut and excision specimens from primary breast cancer 
since clinical management involves assessment of both type 
of samples and particularly in clinical trials, a comparison 
between the two [14]. An extreme loss of staining of pAKT 
and pERK1/2 phosphoproteins was observed in excision 
samples compared with core-cut biopsies, changes that are 
likely related to suboptimal fixation [14]. Our previous study 
called attention to these changes leading to possible bias in 
clinical research and provided key evidence to form the basis 
of future guidelines for companion diagnostic tests [13].
Here, we evaluated whether the novel NanoString method 
of protein quantification using oligonucleotide bar-coded 
antibodies can be applied as an alternative methodology to 
evaluate protein expression in breast cancer formalin-fixed 
paraffin-embedded (FFPE) specimens. In particular, using 
a wide range of antibodies available, we assessed whether 
diagnostic core-cuts fixed immediately at time of procedures 
and surgical excision sections from routinely fixed primary 
breast cancers are affected by the same fixation related dif-
ferences we noted by IHC [14]. This investigation has spe-
cial relevance for “window of opportunity” studies where 
data from core-cuts are commonly compared with data from 
excision specimens from the same patients.
Materials and methods
Sample collection
We accessed tissues collected from a previous study given 
their optimal suitability for answering the central questions 
[14]. Core-cut biopsies (14-gauge needle) and surgical exci-
sion FFPE specimens were both available from 16 patients 
with ER positive primary breast cancer. Samples were from 
patients with a median age of 59 years [interquartile range 
(IQR) = 11; 51–62]. Median tumour size was 33.5  mm 
(IQR = 25; 20–45) and 7 patients (43%) were node-positive.
Core-cut biopsies were taken immediately after tumour 
resection and placed in neutral-buffered formalin. The surgi-
cal excision specimens were also placed in neutral-buffered 
formalin and subjected to the histopathology department’s 
routine fixation for breast tumours: lumpectomy samples 
(50% of the cases) were left unsliced until the next morn-
ing, and mastectomy samples (50%) were sliced at inter-
vals of about 10 mm to allow penetration of formalin. Ethi-
cal approval was provided by the Royal Marsden Hospital 
(RMH) and all patients gave written informed consent.
Protein expression analysis by IHC
The IHC expression of the non-phophorylated proteins 
Ki67, PgR and HER2 and phosphorylated proteins pAKT 
and pERK1/2 by IHC was available from our previous study 
[14]. Briefly, PgR (clone 16), pAKT (Ser473) and pERK1/2 
(Thr202/204) were assessed by H-score. Ki67 (clone MIB-
1) expression was measured by counting the numbers of 
positive and negative staining invasive tumour cells in 10 
high-power fields (10 HPF’s) to derive a percentage of posi-
tive invasive cells staining with any intensity. HER2 was 
categorized as 0, 1+, 2+ or 3+ as per HercepTest™ (Agilent 
Dako, UK) and the American Society of Clinical Oncology/
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College of American Pathologists (ASCO/CAP) guidelines 
[15].
Protein expression analysis by NanoString 
technologies
One 5-µm section from each FFPE block was cut on to a 
slide for protein analysis. A 4-µm section from each was 
also stained with haematoxylin and eosin (H&E) and used to 
identify areas with ≥ 40% invasive tumour cells. Non-inva-
sive tissue areas were needle dissected away from invasive 
disease in the 5-µm sections before incubation of antibody 
mix. The expression of 26 target proteins and 3 controls 
(positive control: Histone H3; negative controls: anti-rab-
bit and anti-mouse IgG antibodies) were measured using 
the  nCounter® Vantage 3D™ Protein Solid Tumor Panel 
for FFPE (NanoString Technologies, Seattle, WA, USA). 
Commercial protocols from NanoString for hybridization 
and detection were followed with minor modifications as 
follows. After deparaffinization and rehydration, epitope 
retrieval was performed with low pH citrate buffer in a Pre-
Treatment-link (Agilent Dako, UK) and samples were incu-
bated overnight with the antibody mix at 4 °C. To cleave 
tags from antibodies, slides were exposed to UV for 3 min 
in UV Stratalinker 1800 (Strategene, USA).The dilution of 
 nCounter® oligonucleotide tags from the bound antibodies 
was optimized based on the analysis of 12 samples (6 core-
cuts; 6 surgical excisions) run with 3 different dilutions. In 
all cases, the results of the 3 dilutions on a single sample 
clustered together on hierarchical clustering (Supplemental 
Fig. 1). Based on these results, cleaved tags were diluted 10x 
prior to denaturation and hybridization with reporter and 
capture probes (NanoString Technologies) since this maxi-
mized the detection of makers with no significant impact on 
background levels. Protein lysates were denatured at 95 °C 
for 5 min before hybridization with TagSet master mix at 
65 °C for 20 h.
Raw counts from the  nCounter® FLEX Analysis System 
(NanoString Technologies) were normalized by the geomet-
ric mean of the counts from the 6 internal ERCC (External 
RNA Controls Consortium) positive controls to take into 
account the efficiency of the hybridization. Background cor-
rection was done by subtracting the geometric mean of the 
6 ERCC negative control probes and then the 2 non-specific 
IgG controls. To adjust for differences in sample input, data 
were normalized to the level of Histone H3, which was con-
firmed to present the lowest variation across the studied sam-
ples. Expression values were log2 transformed for statistical 
analysis. For the direct comparison with IHC data, signals 
from IgG controls were not subtracted.
Zeros values were set as half of lowest expression 
detected for the respective protein.
Statistical analysis
Descriptive data are presented as median and interquartile 
range (IQR). The correlation between protein expression 
by NanoString and IHC was evaluated by Spearman cor-
relation test. Spearman correlation was also carried out to 
investigate the correlation between the proteins. Wilcoxon 
signed-rank test was used to compare the protein expression 
between cores and surgical excisions. Mann–Whitney U test 
was used to investigate whether protein expression varies 
according the type of surgery and to compare protein expres-
sion between clusters of samples. P values were two-sided 
and all confidence intervals were at the 95% level.
Results
Protein expression analysis by NanoString 
technologies is highly correlated with standard IHC
We initially assessed the correlation between the biomarker 
measurements by NanoString and IHC. When considered 
irrespective of sample type, the expression of both phospho-
rylated and non-phosphorylated proteins measured by both 
methods was significantly strong correlated (ρ = 0.69–0.88, 
p < 0.001 for all comparisons; Fig. 1). However, when core-
cuts and surgical excisions were evaluated separately, the 
correlations between NanoString and IHC were weaker but 
still apparent except for pAKT measurements in excisions 
(Fig. 1).
Differences in the phosphoprotein expression 
between core‑cuts and excision specimens
Among the 26 studied proteins, only pEGFR was not 
detected in both core-cut and excision specimens and was 
therefore excluded from the following analysis. Using the 
expression data of the 25 remaining proteins, the studied 
samples were classified by unsupervised 2-way hierarchi-
cal clustering which yielded 2 main clusters in each direc-
tion: for sample type, one cluster was composed by excision 
specimens and another cluster by all core-cuts samples and 
one excision samples; and for protein type, one cluster was 
composed largely of phosphoproteins and one largely by 
non-phosphorylated proteins (Fig. 2).
As previously reported using IHC and in agreement 
with the correlation analysis above described, Ki67, PgR 
and HER2 expression did not differ significantly between 
cores and excisions (p > 0.05; Figs. 2, 3) while pERK1/2 
(14/16 with > 50% reduction; p = 0.003) and pAKT (mean 
reduction = 59.5%; p < 0.001) showed markedly lower lev-
els in the excision samples (Fig. 3). There was also a trend 
for HER2 to be reduced in surgical excisions (p = 0.086) 
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with 8/16 samples showing more than 50% of reduction in 
relation to matched core-cut biopsies.
In addition to pERK1/2 and pAKT, 6 other phos-
phorylated proteins also had significantly lower levels 
in surgical excisions in comparison to paired core-cuts 
(Fig. 3): p4EBP1 (mean reduction = 54.2%; p < 0.001), 
pGSK3B (14/16 with > 75% reduction; p = 0.003), pRPS6 
(mean reduction = 40%; p = 0.005), pAMPKa (mean 
reduction = 55.1%; p < 0.001), pMEK1/2 (mean reduc-
tion = 26.3%; p = 0.008) and pPRAS40 (mean reduc-
tion = 34.1%; p = 0.001). Four phosphorylated proteins 
(pTSC2, pPDK1, pRAF1 and pH3) did not show a signifi-
cant difference in expression between the paired core and 
excision samples.
Differences in the non‑phosphorylated proteins 
expression between core‑cuts and excision 
specimens
Of the 13 non-phosphorylated proteins measured, 4 had 
significantly increased levels in surgical excisions com-
pared to core-cuts (Fig. 3): pan-KRT (13/16 samples with 
> 100% increase; p = 0.001), 4EBP1 (mean increase = 87%; 
p = 0.039), ERK1/2 (mean increase = 69.5%; p = 0.009) 
and MET (mean increase = 27.9%; p = 0.034) and none 
had significantly decreased levels.
Fig. 1  Correlation between protein expression measured by 
NanoString and IHC. Green dots: core-cut biopsies; Dark pink: exci-
sion samples. Coefficient of correlation (ρ) and p-value by Spearman 
correlation test are shown. PgR antibody recognizes different regions 
in NanoString (isoform B) and IHC (isoform A and B as routinely 
applied in clinical practice)
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Difference in the protein levels with the type 
of surgery and tumour size
As expected, tumours were larger in patients treated 
with mastectomy (median = 45.5 mm, IQR = 24.5) com-
pared to lumpectomy (median = 21  mm, IQR = 14.75; 
p = 0.015). The difference in immunogenicity between 
paired core-cuts and surgical excisions was signifi-
cantly correlated with tumour size for 4 markers (Fig. 4): 
p4EBP1 (p = 0.006; ρ = − 0.653), pAMPKa (p = 0.032; 
ρ = − 0.536), pRPS6 (p = 0.005, ρ = − 0.666) and pRAF1 
(p = 0.003; ρ = − 0.696). The difference in expression of 
p4EBP1 (p = 0.021) and pRPS6 (p < 0.0001) between 
paired core-cuts and surgical excisions was also signifi-
cant in mastectomy compared with lumpectomy (Fig. 4).
Correlation between differences 
in non‑phosphoproteins and phosphorylated 
proteins immunoreactivity
Since the difference in the expression of phosphorylated pro-
teins between core-cuts and excision specimens may be a 
result of delayed fixation process, we also evaluated whether 
the difference between core-cuts and surgical excisions in 
the expression of phosphorylated and non-phosphorylated 
proteins were correlated. In general, most of the phospho-
protein differences were strongly correlated with one another 
and most of non-phosphorylated proteins were also strongly 
correlated with one another (Supplemental Fig. 2). The 
mean difference of all phosphorylated proteins was corre-
lated with that of all non-phosphorylated proteins (p < 0.001; 
Fig. 2  Heatmap based on 
Spearman Correlation test. 
Columns values were scaled by 
log2 difference in relation to 
the mean of each protein. Grey: 
non-phosphorylated proteins; 
orange: phosphorylated pro-
teins; Green: core-cut biopsies; 
Pink: excisions/mastectomy; 
Purple: excisions/lumpectomy
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ρ = 0.785; Supplemental Fig. 3). The mean difference of 
phosphorylated proteins immunoreactivity was correlated 
with changes of 8/13 non-phosphorylated proteins (Supple-
mental Figs. 2 and 3): 4EBP1 (p = 0.019; ρ = 0.588), ERK1/2 
(p = 0.028; ρ = 0.556), GSK3B (p < 0.001; ρ = 0.800), HER2 
(p < 0.001; ρ = 0.841), Ki67 (p = 0.003; ρ = 0.697); MET 
(p = 0.018; ρ = 0.591), pan-AKT (p = 0.004; ρ = 0.697), 
TSC2 (p = 0.001; ρ = 0.741). These significant positive cor-
relations were despite the mean level of some of non-phos-
phorylated proteins being significantly higher in surgical 
excisions than core-cuts and the overall mean level of the 
phosphorylated proteins being significantly reduced.
Discussion
The quantification of protein expression in FFPE samples, 
the most frequently available tissue for analysis, is usually 
performed with low throughput/singleplex methods such as 
standard IHC. Although several advances over the last years 
have been described for quantification of IHC i.e. digital 
analysis and IF staining, IHC still has several limitations 
and relatively low throughput. Large-scale analyses of pro-
teins by mass spectrometry have also been developed, but 
this technique requires high level of specialization for meas-
urement and data analysis [16]. On the other hand, gene 
expression molecular assays have gained widespread use to 
allow fast and sensitive quantification of thousands of genes 
[17]. Recently, panels of DNA bar-coded antibodies have 
become available that allow rapid and simultaneous meas-
urement of multiple proteins. The method described here 
applies the same end-technology currently used for RNA and 
DNA analysis on the NanoString nCounter platform with 
general high sensitivity and reproducibility [12]. Notewor-
thily, only pEGFR had counts below that detected for IgG 
antibodies (controls for non-specific binding) in all samples. 
These data agree with the consistent reports of very low 
expression of EGFR in ER positive breast cancer which our 
Fig. 3  Comparison between cores and surgical excisions specimens. 
pEGFR was not detected above background in the studied samples 
and it is not shown. Pink: mastectomy. Purple: lumpectomy. p-value 
of Wilcoxon signed-rank test is shown. Zero values were set as half of 
the lowest expression detected of the respective protein
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cohort was formed from exclusively [18, 19]. However, since 
this method is still based on antigen–antibody binding, the 
effect of pre-analytical variables needs to be characterized 
to ensure reproducibility and analytic validity before wide-
spread use in investigations using clinical FFPE samples.
Our data show a strong correlation between standard IHC 
and NanoString technology for protein expression analysis 
providing initial support for the validity of the NanoString 
technique in both core-cuts and surgical excisions. We esti-
mated that in our previous study [14] 7 h bench time was 
necessary to score Ki67, PgR, HER2, pAKT and pERK1/2 
for 12 samples. In contrast, approximately 2 h bench time 
(including incubation time) was necessary to perform all 
the steps after antibody incubation to obtain the normalized 
counts for 26 proteins in 12 samples (a batch) using the new 
technology. While the higher cost of this new approach is 
likely to prevent it replacing IHC for the small number of 
biomarkers routinally measured in primary breast cancer, it 
may be cost-effective in clinical research protocols that often 
include the assessment of large number of biomarkers par-
ticularly phosphorylated markers [20]. Another advantage of 
the NanoString approach is its inclusion of within-sample 
housekeeping probes (such as Histone 3) that help to correct 
for variability in the analytical process.
The result of the PgR expression comparison between the 
two techniques should be interpreted with caution. In the 
IHC, we used an antibody that recognizes both isoforms A 
and B of PgR as is standard clinical practice. On the other 
hand, only isoform B was measured using the  nCounter® 
Vantage 3D™ Panel for FFPE, limiting our interpretation. 
Currently the commercial panel of Nanostring reagents does 
not include an antibody-probe to oestrogen receptor although 
this is a widely measured analyte. Given the overall encour-
aging data derived and reported here we have initiated a 
bespoke assessment of oestrogen receptor with NanoString 
technology.
Fig. 4  Phosphorylation immunogenicity and tumour size or type of 
surgery. Pink: mastectomy. Purple: lumpectomy. For tumour size, 
p-value and coefficient of correlation (ρ) of Spearman Correlation 
test are shown. For type of surgery, p-value of Mann–Whitney U test 
is shown. Difference = log2(Excision) − log2(Core-cut). Zero values 
were set as half of the lowest expression detected of the respective 
protein
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The comparison of measurements between core-cuts and 
surgical excisions revealed a large number of differences 
that could cause major inaccuracies if not recognized. Only 
2 surgical excisions showed mean phosphorylation higher 
than in core-cuts from the same tumours and a dramatically 
lower level of most of the phosphorylated proteins (8/12) 
immunoreactivity was detected in tumour excisions, includ-
ing the loss of pERK1/2 and pAKT as previously reported 
[14, 21, 22]. This systematic change between core-cuts and 
surgical excisions is most likely to be a result of a longer 
time to achieve fixation in the excision samples. At room 
temperature and without fixation accelerators, formalin pen-
etrates tissue at about 1 mm/h [23]. Thus core-cuts (small 
volume) are rapidly fixed after immersion in formalin. Con-
versely, formalin penetration of the larger volume speci-
mens is a slower process, which results in greater loss of 
biomarker immunoreactivity. The effect of the delay fixation 
in larger volume specimens was confirmed directly for some 
markers in this study and further supported by the greater 
reduction of phosphorylated protein expression in mastec-
tomies compared to lumpectomies. Although ASCO/CAP 
guidelines suggest samples reach fixative in less than 1 h 
for analysis of common biomarkers in clinical practice [4, 
15], our findings support the suggestion by Ibarra et al. that 
more focus should be given on time before fixation of thinly 
sliced specimens rather than the time the tissue remains in 
formalin [24].
The extreme loss of phosphorylated protein expression 
can lead to difficult or even erroneous interpretation of data 
in clinical studies involving excision specimens. Phosphoryl-
ated proteins are often considered as biomarkers of active 
kinase signalling pathways and the reduction in the level 
of such proteins as indices of inhibition of the respective 
pathways. In breast cancer, the “window of opportunity” 
between diagnosis and surgical excision has frequently been 
exploited to assess the biological impact of medical treat-
ments [25–27]. Comparisons between the routinely available 
diagnostic core-cuts and surgical excisions in that scenario 
could lead to reductions in levels of phosphoproteins being 
erroneously interpreted as indicating pharmacologic activ-
ity of the respective agent. Some phosphoproteins are more 
labile, such as pERK1/2 [21], and thus it is expected that the 
impact of delay in fixation will vary according the type of 
surgery as well as the size of tumour. Consistent with this 
there was a small number of phosphoproteins in the panel 
examined that were not significantly different in their expres-
sion between core-cuts and surgical excisions. The key mes-
sage is to be aware that many phosphoproteins are grossly 
affected by the sample type/fixation time but it should not 
be assumed that a particular phospho-marker of interested 
is affected: it should be tested. While this loss of phospho-
protein immunoreactivity is an issue that is best avoided in 
clinical protocols, the inclusion of paired cores and excision 
samples in our study allowed us to demonstrate the similar 
impact of the artefact with both methods.
Although a consistently lower expression of most phos-
phoproteins expression was detected in excision specimens, 
the non-phosphorylated proteins pan-KRT, MET, 4EBP1 
and ERK1/2 showed significantly high expression these 
samples. Given this, it was initially surprising to observe 
that there was a significant positive correlation between the 
overall difference in expression of phosphoproteins between 
core-cuts and surgical excisions with the expression of these 
non-phosphoproteins. A possible explanation of this is that 
the increased expression of the non-phosphoproteins may 
be due to a stress response, including to hypoxia [28]. For 
example, increased of expression of ERK1/2 may be related 
to its role in survival under hypoxia conditions in breast 
cancer cells [29]. We have observed increases in many RNA 
transcripts in samples with just a 20–60 min delay before fix-
ation [30, 31]. The correlation could then be also explained 
by these non-phosphoproteins also being labile such that the 
apparently lesser degree of difference in expression between 
some core-cuts and surgical excisions would be found in 
those paired samples where delays to fixation were greatest.
The present study has some limitations. Firstly, the num-
ber of samples analysed was relatively small: it was clearly 
sufficient to demonstrate the compatibility of major breast 
cancer biomarker and of the differences between core-cuts 
and surgical excisions; however, larger numbers would be 
needed to identify any problems that might occur in some 
other sample types. Secondly, only 5 proteins were com-
pared between NanoString technology and standard IHC. 
Thirdly, samples were collected and the original IHC data 
obtained in 2008–2009, in 8–9 years before NanoString 
analysis was performed. Antigenicity, however, is largely 
stable in tumour blocks as used here as opposed to stored 
sections [28] and the strong correlation seen between the 
technologies and between markers suggests this was not a 
significant limitation. Third, the studied sample was com-
posed by only ER+ tumours and only one case was classified 
as HER2+ by IHC analysis. Therefore, cohorts of HER2+ 
tumours should be assessed to determine the ability of this 
technology to segregate HER2− and HER2+ tumours reli-
ably. Lastly, due to the exploratory nature of the study, we 
did not correct for multiple comparisons involving 25 pro-
teins and acknowledge that false-positives may have arisen. 
It should also be noted that NanoString technology does not 
take into consideration the pathologists’ assignment of the 
location of the positive cells as in IHC; however, we dis-
sected away the non-invasive tissue areas prior the antibody 
incubation to reduce the impact of benign tissue.
In conclusion, our study provides preliminary support 
for the analytic validity of the new bar-coded multiplex 
approach to protein analysis but indicates that as with IHC 
caution is necessary for the analysis in surgical excisions 
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specimens particularly of many phosphoproteins. The type 
of tissue specimen and type of surgery may act as confound-
ing factors in drug discovery or development of companion 
diagnostic tests based on protein analysis.
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